{"nctId":"NCT03967054","briefTitle":"Repeat Ivermectin Mass Drug Administrations for MALaria Control II","startDateStruct":{"date":"2019-07-13","type":"ACTUAL"},"conditions":["Malaria"],"count":4124,"armGroups":[{"label":"Ivermectin mass drug administration","type":"EXPERIMENTAL","interventionNames":["Drug: Ivermectin"]},{"label":"Placebo mass administration","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo oral tablet"]}],"interventions":[{"name":"Ivermectin","otherNames":["Iver P"]},{"name":"Placebo oral tablet","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria (for being enrolled in the study):\n\n* Residence in selected study village\n* Able to understand the information and willing to give consent or assent (age 12-18) and parent/guardian consent if study participant age is \\< 18 years of age.\n\nExclusion Criteria (for participating in the intervention \\[ivermectin or placebo MDA\\]):\n\n* Residence outside of the study village\n* Height \\< 90 cm (\\*note: if subject becomes ≥90cm over course the trial, this exclusion criteria will no longer be valid in subsequent MDA)\n* Current treatment with SP+AQ as part of SMC (restricted to children 3-59 months old) (\\*note: if subject discontinuous SP+AQ treatment because they become older than 59 months over course the trial, this exclusion criteria will no longer be valid in subsequent MDA)\n* Permanent disability or serious medical illness that prevents or impedes study participation and/or comprehension\n* Pregnancy (screened for in women of child-bearing age \\[ages 15-45\\] using a pregnancy urine rapid test \\[e.g. SD Bioline hCG\\] the week prior to each MDA)\n* Breast feeding if infant is within 1 week of birth\n* Known allergy to ivermectin\n* Possibility of Loa loa infection as assessed by travel history to Angola, Cameroon, Chad, Central African Republic, Congo, Democratic Republic of Congo, Equatorial Guinea, Ethiopia, Gabon, Nigeria, and Sudan.\n* Enrolled in any other active clinical trials","healthyVolunteers":true,"sex":"ALL","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Malaria Incidence","description":"Incidence of malaria episodes in enrolled village children ≤ 10 years of age","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0176","spread":null},{"groupId":"OG001","value":"0.0183","spread":null}]}]}]},{"type":"SECONDARY","title":"Adverse Events","description":"Number adverse events among the study population over the course of the intervention period. Note, this number includes all malaria cases that were part of the primary outcome that occurred in the cohort of children that were actively assessed for malaria on a weekly basis during the intervention.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"438","spread":null},{"groupId":"OG001","value":"402","spread":null}]}]}]},{"type":"SECONDARY","title":"Survival Rate of Blood Fed Mosquitoes","description":"Number of Blood Fed Mosquitoes Alive For 3 Days After Capture","paramType":"COUNT_OF_UNITS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"399","spread":null},{"groupId":"OG001","value":"896","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":8,"n":2191},"commonTop":["malaria","upper respiratory infection","pruritis","fever","rash"]}}}